Should Investors Avoid Concordia Healthcare Corp.?

Concordia Healthcare Corp. (TSX:CXR)(NASDAQ:CXRX) is being held back due to political pressure on a competitor, but does the recent acquisition make Concordia a buy? It just might…

The Motley Fool

Canadian healthcare stocks don’t exactly appear to be the best investments right now, what with the recent political pressure that Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been coming under. As is typically the case in the markets, when one stock gets knocked off its pedestal, others tend to follow and that’s what’s happened with Concordia Healthcare Corp. (TSX:CXR)(NASDAQ:CXRX).

Because of a near-perfect storm, Concordia had selling pressure that was amplified when the news came out that Valeant was under investigation.

Here’s why Concordia was targeted: Valeant buys companies, slashes R&D expenses, and increases the price of drugs. That’s part of how it has been growing. Concordia does the exact same thing. Therefore, if Valeant is going to get in trouble for doing this, investors were concerned that Concordia would be in trouble as well.

The problems started because of the announcement that Concordia was acquiring Amdipharm, a U.K.-based company. This would have given Concordia, which has a 100% dependence on the United States, access to 100 markets that Amdipharm sells its pharmaceuticals in.

And there was good news about the deal. According to the company, adjusted EBITDA would soar in 2016 to US$510-540. The problem was that the company was going to need to borrow US$2.8 billion to finance the deal, which would have given it a lot of debt at an interest rate not very borrower friendly.

Should investors avoid it?

There are two ways to look at that question. One the one hand, it could continue to be held back by Valeant’s problems. At this point in time Concordia is not under investigation from any government. But investors could remain spooked because they don’t want to get hurt by Valeant’s problems.

However, on the other hand, the acquisition is also a very good deal if it can handle the debt load. Amdipharm allows Concordia to diversify its business around the world and it ensures that no one drug becomes the dominant money maker. This is important in the drug business because a company can be just one generic drug away from losing its dominance in the market.

My advice when it comes to these kinds of companies is simple: if it’s going to keep you up at night, avoid it. While I believe the markets are not treating Concordia fairly, that could continue for some time. Therefore, if holding a stock like this will keep you awake, just avoid it. There are plenty of other great companies out there.

However, if you can handle the potential volatility and want to acquire shares in a company that are, by and large, very attractively priced, then I would advise starting a position. Valeant’s got the problem, not Concordia. And the recent acquisition is a good move for the company so long as debt doesn’t hold it back.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

jar with coins and plant
Dividend Stocks

How Much to Invest in TC Energy for $142 a Quarter in Dividends

With predictable cash flows, consistent dividend growth, an attractive yield, and clear growth opportunities, TC Energy is ideal for income-seeking…

Read more »

Digital background depicting innovative technologies in (AI) artificial systems, neural interfaces and internet machine learning technologies
Tech Stocks

Where Could Celestica Stock Be in 5 Years? What the New Outlook Means

Celestica’s ambitious 2027 outlook and accelerating AI infrastructure demand could fuel its next phase of growth, making its recent stock…

Read more »

man in bowtie poses with abacus
Dividend Stocks

How Much Would You Need in SmartCentres to Collect $250 a Month?

SmartCentres can pay an actual monthly distribution. Reaching $250 from it alone would require nearly $45,000 at recent prices.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Stock Market

One ETF or Several? How to Keep Your Investments as Simple as Possible

Here's how choosing the right mix of ETFs could help you simplify your investments while building long-term wealth.

Read more »

ETFs can contain investments such as stocks
Dividend Stocks

1 Top Dividend ETF to Buy to Generate Passive Income

Vanguard's VDY pays monthly with a 0.22% MER and a 3% yield. See what $20,000 could earn, the bank and…

Read more »

groceries get more expensive as inflation rises
Dividend Stocks

2 TSX Giants to Buy for Decades of Growth and Dividends

Royal Bank of Canada (TSX:RY) and another dividend giant worth buying up for decades.

Read more »

ETF stands for Exchange Traded Fund
Dividend Stocks

2 of the Best ETFs to Buy Now

Looking for the best ETFs to buy now? Explore how XEQT offers global stock exposure while ZAG adds Canadian bonds…

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Dividend Stocks

A TFSA-Worthy Dividend Stock Paying 5.1% Monthly

Choice Properties could be a great monthly dividend stock for TFSA investors seeking attractive passive income and long-term growth potential.

Read more »